BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/6/2019 11:50:46 AM | Browse: 947 | Download: 1085
 |
Received |
|
2019-04-08 00:55 |
|
Peer-Review Started |
|
2019-04-08 06:48 |
|
To Make the First Decision |
|
2019-06-03 04:11 |
|
Return for Revision |
|
2019-06-17 01:20 |
|
Revised |
|
2019-06-21 17:42 |
|
Second Decision |
|
2019-07-02 10:10 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-07-03 16:54 |
|
Articles in Press |
|
2019-07-03 16:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-07-12 07:33 |
|
Typeset the Manuscript |
|
2019-07-31 07:01 |
|
Publish the Manuscript Online |
|
2019-08-06 11:50 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li-Tong Yao, Mo-Zhi Wang, Meng-Shen Wang, Xue-Ting Yu, Jing-Yi Guo, Tie Sun, Xin-Yan Li and Ying-Ying Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the National Natural Science Foundation of China |
No.81773083 |
|
| Corresponding Author |
Ying-Ying Xu, PhD, Professor, Department of Breast Surgery, the First Affiliated Hospital of China Medical University, No. 155 North Nanjing Street, Shenyang 110001, Liaoning Province, China. xuyingying@cmu.edu.cn |
| Key Words |
Breast cancer; Neoadjuvant endocrine therapy; Neoadjuvant chemotherapy; Aromatase inhibitor; Palbociclib; Ki67 |
| Core Tip |
Neoadjuvant endocrine therapy (NAE), both alone or accompanying with other therapies, is a valuable alternate approach to ER-positive breast cancer. Our object is to define the optimal settings for suitable individuals, including optimal treatment duration, endocrine agents and targeted agents in NAE. The identification of correct patients for NAE remains unknown and requires further validation corresponding to biomarker-based strategies. This review consolidates the current relevant evidence to verify the potential value and discuss the development prospects of NAE. |
| Publish Date |
2019-08-06 11:50 |
| Citation |
Yao LT, Wang MZ, Wang MS, Yu XT, Guo JY, Sun T, Li XY, Xu YY. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World J Clin Cases 2019; 7(15):1937-1953 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i15/1937.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i15.1937 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
